February 24, 2020
Fremont, Calif.—Verseon is pleased to announce that Dr. Francis J. Doyle, III, Dean of Harvard’s School of Engineering and Applied Sciences, has joined the company’s scientific advisory board. He brings vast experience in computational systems biology to our advisory board.
Frank has been a member of the National Academy of Medicine since 2016. He is also the John A. and Elizabeth S. Armstrong Professor of Engineering and Applied Sciences. In addition, Frank is affiliated with the Division of Sleep Medicine of Harvard Medical School. His primary teaching area is bioengineering.
As co-principal investigator of the artificial pancreas project, Frank leads a multidisciplinary team of engineers and scientists who are developing algorithms to automate an insulin delivery system to regulate the blood sugar levels of individuals with type 1 diabetes mellitus.
Frank’s research group also studies circadian rhythms, employing control-systems insights to unravel and manipulate the underlying biological regulatory circuits. In addition, his team builds statistical and mathematical models to gain insights into the mechanisms of, and biomarkers for, post-traumatic stress disorder (PTSD).
A distinguished scholar in chemical engineering, Frank previously served as Associate Dean for Research at the University of California, Santa Barbara's College of Engineering, where he also served as chair of the Department of Chemical Engineering. At UCSB he was a founding co-Director of the UCSB-MIT-Caltech Institute of Collaborative Biotechnologies.
Prior to his appointment at UCSB, Frank was a professor in the Department of Chemical Engineering at the University of Delaware from 1997 to 2002, and was a professor in the School of Chemical Engineering at Purdue University from 1992 to 1997. Before his first academic appointment, he did postdoctoral studies at the DuPont Company.
Verseon Corporation (www.verseon.com) is developing disruptive life-science technology to advance global health. The clinical-stage company is using its proprietary, computational drug discovery platform to discover new drug candidates that are unlikely to be found using conventional methods. Pairing its computational platform with a comprehensive in-house chemistry and biology workflow, the company has built a growing pipeline of drug programs. Verseon currently has drug programs in the areas of anticoagulation, diabetic retinopathy, hereditary angioedema, and oncology.